WO2005085209A1 - アミン系塩基性化合物とその用途 - Google Patents
アミン系塩基性化合物とその用途 Download PDFInfo
- Publication number
- WO2005085209A1 WO2005085209A1 PCT/JP2005/004189 JP2005004189W WO2005085209A1 WO 2005085209 A1 WO2005085209 A1 WO 2005085209A1 JP 2005004189 W JP2005004189 W JP 2005004189W WO 2005085209 A1 WO2005085209 A1 WO 2005085209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- ylmethyl
- imidazole
- amino
- butyl
- Prior art date
Links
- -1 amine compound Chemical class 0.000 title claims abstract description 212
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 53
- 125000003118 aryl group Chemical group 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 27
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 19
- 125000003367 polycyclic group Chemical group 0.000 claims abstract description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 471
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 333
- 239000000203 mixture Substances 0.000 claims description 318
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 136
- 125000004432 carbon atom Chemical group C* 0.000 claims description 90
- 229920006395 saturated elastomer Polymers 0.000 claims description 77
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 26
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 25
- 239000000651 prodrug Substances 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 19
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 14
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- URMIRVBFOWMXMV-UHFFFAOYSA-N 3-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]propanoic acid Chemical compound C1=CC(CN(CCC(O)=O)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 URMIRVBFOWMXMV-UHFFFAOYSA-N 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 7
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 7
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- FCISHAUCAFRFDC-UHFFFAOYSA-N 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoic acid Chemical compound C1=CC(CN(CCC(O)=O)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 FCISHAUCAFRFDC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 3
- DJNAYWDSMMINQB-UHFFFAOYSA-N 2-[[4-(dipropylamino)butyl-methylamino]methyl]-5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzoic acid Chemical compound C1=C(C(O)=O)C(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 DJNAYWDSMMINQB-UHFFFAOYSA-N 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- MWEGWMOWLVZLJS-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-4-methylbenzenesulfonamide Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)N(CCCCN(CCC)CCC)CC(C=C1)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 MWEGWMOWLVZLJS-UHFFFAOYSA-N 0.000 claims description 3
- BWSMKGHXMYFQGB-SANMLTNESA-N (2s)-5-(dipropylamino)-2-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl-methylamino]pentanoic acid Chemical compound C1=CC(CN(C)[C@@H](CCCN(CCC)CCC)C(O)=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 BWSMKGHXMYFQGB-SANMLTNESA-N 0.000 claims description 2
- UVMWRDMGNBNBPD-UHFFFAOYSA-N 2-[2-[[[4-[[4-(dipropylamino)butyl-methylamino]methyl]phenyl]methyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]imidazol-1-yl]acetic acid Chemical compound C1=CC(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)CC(O)=O)CC1=NC=CN1C UVMWRDMGNBNBPD-UHFFFAOYSA-N 0.000 claims description 2
- FEPMJQULJFFXJP-UHFFFAOYSA-N 2-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]ethanol Chemical compound C1=CC(CN(CCO)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 FEPMJQULJFFXJP-UHFFFAOYSA-N 0.000 claims description 2
- IYBVSXRIOPQVNA-UHFFFAOYSA-N 2-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]acetic acid Chemical compound C1=CC(CN(CC(O)=O)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 IYBVSXRIOPQVNA-UHFFFAOYSA-N 0.000 claims description 2
- PBUQIWPMDMYVRL-UHFFFAOYSA-N 2-[[4-[[bis[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]acetic acid Chemical compound C1=CC(CN(CC(O)=O)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1C PBUQIWPMDMYVRL-UHFFFAOYSA-N 0.000 claims description 2
- XTWWKTHQLGNXOR-UHFFFAOYSA-N 4-[6-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]-1-propylbenzimidazol-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C1=C2N(CCC)C(CCCCN(CCC)CCC)=NC2=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 XTWWKTHQLGNXOR-UHFFFAOYSA-N 0.000 claims description 2
- TYUQDFGPGMQZJV-UHFFFAOYSA-N 4-[[4-(dipropylamino)butyl-methylamino]methyl]-n-(1h-imidazol-2-ylmethyl)-n-[(1-methylimidazol-2-yl)methyl]benzamide Chemical compound C1=CC(CN(C)CCCCN(CCC)CCC)=CC=C1C(=O)N(CC=1N(C=CN=1)C)CC1=NC=CN1 TYUQDFGPGMQZJV-UHFFFAOYSA-N 0.000 claims description 2
- IJBGVWJGMBOFAU-UHFFFAOYSA-N CCCN(CCC)CCCCN(CC1=CC=C(C=C1)CN(CC2=NC=CN2)CC3=NC=CN3C)C(C)CCOC(=O)CC Chemical compound CCCN(CCC)CCCCN(CC1=CC=C(C=C1)CN(CC2=NC=CN2)CC3=NC=CN3C)C(C)CCOC(=O)CC IJBGVWJGMBOFAU-UHFFFAOYSA-N 0.000 claims description 2
- JGNUXWNWTWQDOV-UHFFFAOYSA-N CCCN(CCC)CCCCN(CCOC(=O)C)CC1=CC=C(C=C1)CN(CC2=NC=CN2)CC3=NC=CN3 Chemical compound CCCN(CCC)CCCCN(CCOC(=O)C)CC1=CC=C(C=C1)CN(CC2=NC=CN2)CC3=NC=CN3 JGNUXWNWTWQDOV-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- NFDQJEATYVVMLK-PBBFAOSKSA-N [(2r)-oxolan-2-yl]methyl 2-[4-(dipropylamino)butyl-[2-[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]-1-phenylethyl]amino]acetate Chemical compound N=1C=CNC=1CN(CC=1N(C=CN=1)C)CC(C=1C=CC=CC=1)N(CCCCN(CCC)CCC)CC(=O)OC[C@H]1CCCO1 NFDQJEATYVVMLK-PBBFAOSKSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- XXJCMVVJGKRNNS-UHFFFAOYSA-N benzyl 2-[4-(dipropylamino)butyl-[2-[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]-1-phenylethyl]amino]acetate Chemical compound N=1C=CNC=1CN(CC=1N(C=CN=1)C)CC(C=1C=CC=CC=1)N(CCCCN(CCC)CCC)CC(=O)OCC1=CC=CC=C1 XXJCMVVJGKRNNS-UHFFFAOYSA-N 0.000 claims description 2
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 2
- WJSDHUCWMSHDCR-VMPITWQZSA-N cinnamyl acetate Natural products CC(=O)OC\C=C\C1=CC=CC=C1 WJSDHUCWMSHDCR-VMPITWQZSA-N 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
- CNYSCJLONZKEDS-UHFFFAOYSA-N methyl 3-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OC)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 CNYSCJLONZKEDS-UHFFFAOYSA-N 0.000 claims description 2
- RBUFYFRYZSWVCF-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]methanesulfonamide Chemical compound C1=CC(CN(CCCCN(CCC)CCC)S(C)(=O)=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 RBUFYFRYZSWVCF-UHFFFAOYSA-N 0.000 claims description 2
- ITILUOVNZKEUNE-UHFFFAOYSA-N n-[4-[(dipropylamino)methyl]phenyl]-4-[[(5-ethylpyridin-2-yl)methyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CN(CC=1N=CC(CC)=CC=1)CC1=NC=CN1C ITILUOVNZKEUNE-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 2
- VIUMMKOXTCFHFC-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound O1C(=O)C2=CC=CC=C2C1OC(=O)CCN(CCCCN(CCC)CCC)CC(C=C1)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 VIUMMKOXTCFHFC-UHFFFAOYSA-N 0.000 claims 1
- QDCHQKMWIHQKPP-UHFFFAOYSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C=1C=C(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)C=CC=1CN(CCCCN(CCC)CCC)CCC(=O)OCC=1OC(=O)OC=1C QDCHQKMWIHQKPP-UHFFFAOYSA-N 0.000 claims 1
- HZWXDTFSYJIYFN-UHFFFAOYSA-N 1-cyclohexyloxycarbonyloxyethyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C=1C=C(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)C=CC=1CN(CCCCN(CCC)CCC)CCC(=O)OC(C)OC(=O)OC1CCCCC1 HZWXDTFSYJIYFN-UHFFFAOYSA-N 0.000 claims 1
- LHNDADQTLFKQBL-UHFFFAOYSA-N 2-[4-(dipropylamino)butyl-[[4-[[1H-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanedioic acid Chemical compound CCCN(CCC)CCCCN(CC1=CC=C(C=C1)CN(CC2=NC=CN2)CC3=NC=CN3C)C(C(=O)O)C(=O)O LHNDADQTLFKQBL-UHFFFAOYSA-N 0.000 claims 1
- ORVWXMLQNSQNEA-UHFFFAOYSA-N 2-morpholin-4-ylethyl 2-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]acetate Chemical compound C=1C=C(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)C=CC=1CN(CCCCN(CCC)CCC)CC(=O)OCCN1CCOCC1 ORVWXMLQNSQNEA-UHFFFAOYSA-N 0.000 claims 1
- VOOHIELVRDEBSB-UHFFFAOYSA-N 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoyloxymethyl 3-cyclopentylpropanoate Chemical compound C=1C=C(CN(CC=2NC=CN=2)CC=2N(C=CN=2)C)C=CC=1CN(CCCCN(CCC)CCC)CCC(=O)OCOC(=O)CCC1CCCC1 VOOHIELVRDEBSB-UHFFFAOYSA-N 0.000 claims 1
- LSBHJMHHXVGQFA-UHFFFAOYSA-N 4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]cyanamide Chemical compound C1=CC(CN(CCCCN(CCC)CCC)C#N)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 LSBHJMHHXVGQFA-UHFFFAOYSA-N 0.000 claims 1
- RDTDTRFVTKCZQO-UHFFFAOYSA-N 4-[6-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C=1C=C2CN(CCCCN(CCC)CCC)CCC2=CC=1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 RDTDTRFVTKCZQO-UHFFFAOYSA-N 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 229940113088 dimethylacetamide Drugs 0.000 claims 1
- BIDQQGDJRRAGTI-UHFFFAOYSA-N ethoxycarbonyloxymethyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OCOC(=O)OCC)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 BIDQQGDJRRAGTI-UHFFFAOYSA-N 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- LEENMRYNSJIWII-UHFFFAOYSA-N methyl 2-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]acetate Chemical compound C1=CC(CN(CC(=O)OC)CCCCN(CCC)CCC)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 LEENMRYNSJIWII-UHFFFAOYSA-N 0.000 claims 1
- 229940017219 methyl propionate Drugs 0.000 claims 1
- UUBCOUGNBOORSZ-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]formamide Chemical compound C1=CC(CN(CCCCN(CCC)CCC)C=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 UUBCOUGNBOORSZ-UHFFFAOYSA-N 0.000 claims 1
- KLZTUEYLXODSNL-UHFFFAOYSA-N pentan-3-yloxycarbonyloxymethyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OCOC(=O)OC(CC)CC)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 KLZTUEYLXODSNL-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 20
- 239000001257 hydrogen Substances 0.000 abstract description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 206010027476 Metastases Diseases 0.000 abstract description 5
- 230000009401 metastasis Effects 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 101100495924 Arabidopsis thaliana DRD1 gene Proteins 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 654
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 512
- 239000002904 solvent Substances 0.000 description 278
- 238000006243 chemical reaction Methods 0.000 description 270
- 239000000243 solution Substances 0.000 description 261
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 237
- 230000002829 reductive effect Effects 0.000 description 215
- 238000003786 synthesis reaction Methods 0.000 description 200
- 230000015572 biosynthetic process Effects 0.000 description 188
- 239000012044 organic layer Substances 0.000 description 158
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 151
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 149
- 238000010898 silica gel chromatography Methods 0.000 description 138
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 133
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 126
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 118
- 239000007864 aqueous solution Substances 0.000 description 118
- 239000007787 solid Substances 0.000 description 104
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 95
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 92
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 85
- 238000001914 filtration Methods 0.000 description 84
- 238000005160 1H NMR spectroscopy Methods 0.000 description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 73
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 58
- 235000017557 sodium bicarbonate Nutrition 0.000 description 58
- 239000003921 oil Substances 0.000 description 56
- 235000019198 oils Nutrition 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 50
- 229960000583 acetic acid Drugs 0.000 description 47
- 238000003756 stirring Methods 0.000 description 47
- 239000012279 sodium borohydride Substances 0.000 description 46
- 229910000033 sodium borohydride Inorganic materials 0.000 description 46
- 238000001816 cooling Methods 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 39
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 32
- 235000019341 magnesium sulphate Nutrition 0.000 description 32
- 239000002274 desiccant Substances 0.000 description 31
- 239000012153 distilled water Substances 0.000 description 31
- 239000012299 nitrogen atmosphere Substances 0.000 description 26
- 239000012230 colorless oil Substances 0.000 description 25
- 238000010992 reflux Methods 0.000 description 25
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 24
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 23
- UEBFLTZXUXZPJO-UHFFFAOYSA-N 1-methylimidazole-2-carbaldehyde Chemical compound CN1C=CN=C1C=O UEBFLTZXUXZPJO-UHFFFAOYSA-N 0.000 description 22
- 238000001035 drying Methods 0.000 description 21
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 18
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 17
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 16
- 238000001704 evaporation Methods 0.000 description 16
- 239000012280 lithium aluminium hydride Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 10
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 10
- 239000001476 sodium potassium tartrate Substances 0.000 description 10
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- 230000003042 antagnostic effect Effects 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229940095064 tartrate Drugs 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 239000003957 anion exchange resin Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229910052573 porcelain Inorganic materials 0.000 description 4
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- OAKURXIZZOAYBC-UHFFFAOYSA-M 3-oxopropanoate Chemical compound [O-]C(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- QSWUVHDOINBDTO-UHFFFAOYSA-N N-[4-(dipropylamino)butyl]pyridine-2-carboxamide Chemical compound C(CC)N(CCCCNC(=O)C1=NC=CC=C1)CCC QSWUVHDOINBDTO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PZSMLGOAJXSDMK-UHFFFAOYSA-N (1-methylimidazol-2-yl)methanamine Chemical compound CN1C=CN=C1CN PZSMLGOAJXSDMK-UHFFFAOYSA-N 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N 2,3,5-trimethylpyridine Chemical compound CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2,5-dimethylpyridine Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 description 2
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 2
- XXZCIYUJYUESMD-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(morpholin-4-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCOCC1 XXZCIYUJYUESMD-UHFFFAOYSA-N 0.000 description 2
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 2
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- UNVYIAFUCIQFAY-UHFFFAOYSA-N 3-[6-[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]pyridin-2-yl]-n,n-dipropylpropan-1-amine Chemical compound CCCN(CCC)CCCC1=CC=CC(C=2C=CC(CN(CC=3NC=CN=3)CC=3N(C=CN=3)C)=CC=2)=N1 UNVYIAFUCIQFAY-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 2
- KSONICAHAPRCMV-UHFFFAOYSA-N 5-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2C(=O)CCC2=C1 KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 2
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 2
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methyl urea Chemical compound CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- UHBGYFCCKRAEHA-UHFFFAOYSA-N P-toluamide Chemical compound CC1=CC=C(C(N)=O)C=C1 UHBGYFCCKRAEHA-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- CDQDMLWGTVLQEE-UHFFFAOYSA-N (1-methylimidazol-2-yl)methanol Chemical compound CN1C=CN=C1CO CDQDMLWGTVLQEE-UHFFFAOYSA-N 0.000 description 1
- LGLVVVCSQBZONM-HCCLCSBVSA-N (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentano Chemical compound NC(N)=NCCC[C@@H](NC(=O)C)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(N)=O LGLVVVCSQBZONM-HCCLCSBVSA-N 0.000 description 1
- BWSMKGHXMYFQGB-AREMUKBSSA-N (2r)-5-(dipropylamino)-2-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl-methylamino]pentanoic acid Chemical compound C1=CC(CN(C)[C@H](CCCN(CCC)CCC)C(O)=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 BWSMKGHXMYFQGB-AREMUKBSSA-N 0.000 description 1
- QOZJZUZUCBMBLE-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 3-[[4-[[bis(1h-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl-[4-(dipropylamino)butyl]amino]propanoate Chemical compound O1C(=O)C2=CC=CC=C2C1OC(=O)CCN(CCCCN(CCC)CCC)CC(C=C1)=CC=C1CN(CC=1NC=CN=1)CC1=NC=CN1 QOZJZUZUCBMBLE-UHFFFAOYSA-N 0.000 description 1
- SMIXZZMSWYOQPW-UHFFFAOYSA-N (4-nitrophenyl)methylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=C([N+]([O-])=O)C=C1 SMIXZZMSWYOQPW-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical group C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 125000004816 2,2-dimethylethylene group Chemical group [H]C([H])([H])C([*:2])(C([H])([H])[H])C([H])([H])[*:1] 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical group C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- XIEZOYPQNBDFNE-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl 2-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]acetate Chemical compound C1=CC(CN(CC(=O)OCCOCCO)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 XIEZOYPQNBDFNE-UHFFFAOYSA-N 0.000 description 1
- JDIPKQBKSBWIKU-UHFFFAOYSA-N 2-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1CCl JDIPKQBKSBWIKU-UHFFFAOYSA-N 0.000 description 1
- YUTUUOJFXIMELV-UHFFFAOYSA-N 2-Hydroxy-2-(2-methoxy-2-oxoethyl)butanedioic acid Chemical compound COC(=O)CC(O)(C(O)=O)CC(O)=O YUTUUOJFXIMELV-UHFFFAOYSA-N 0.000 description 1
- STOPIDXKWSCDPF-UHFFFAOYSA-N 2-[2-[[[1-(carboxymethyl)imidazol-2-yl]methyl-[[4-[[4-(dipropylamino)butyl-methylamino]methyl]phenyl]methyl]amino]methyl]imidazol-1-yl]acetic acid Chemical compound C1=CC(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)CC(O)=O)CC1=NC=CN1CC(O)=O STOPIDXKWSCDPF-UHFFFAOYSA-N 0.000 description 1
- GSFPNQBZXFOGNX-UHFFFAOYSA-N 2-[3-(dipropylamino)butyl]-1-(methoxymethoxy)-2,3-dihydro-1h-indene-5-carbonitrile Chemical compound N#CC1=CC=C2C(OCOC)C(CCC(C)N(CCC)CCC)CC2=C1 GSFPNQBZXFOGNX-UHFFFAOYSA-N 0.000 description 1
- KMNMWGPPZMOZDD-UHFFFAOYSA-N 2-[3-[(dipropylamino)methyl]phenyl]-3-methylbenzimidazole-5-carbaldehyde Chemical compound CCCN(CCC)CC1=CC=CC(C=2N(C3=CC(C=O)=CC=C3N=2)C)=C1 KMNMWGPPZMOZDD-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WIVGAPLWLAUJPW-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]-6-chloropyridine Chemical compound ClC1=CC=CC(C=2C=CC(CBr)=CC=2)=N1 WIVGAPLWLAUJPW-UHFFFAOYSA-N 0.000 description 1
- SKNCMPWFYZANDB-UHFFFAOYSA-N 2-[4-[(dipropylamino)methyl]phenyl]-4-methyl-1,3-benzothiazol-6-amine Chemical compound C1=CC(CN(CCC)CCC)=CC=C1C1=NC2=C(C)C=C(N)C=C2S1 SKNCMPWFYZANDB-UHFFFAOYSA-N 0.000 description 1
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- DMKVLMTYLJRMQT-UHFFFAOYSA-N 2-[[4-(6-chloropyridin-2-yl)phenyl]methyl]isoindole-1,3-dione Chemical compound ClC1=CC=CC(C=2C=CC(CN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=N1 DMKVLMTYLJRMQT-UHFFFAOYSA-N 0.000 description 1
- GSRCVVJYCDYXQC-UHFFFAOYSA-N 2-[[4-[6-[3-(dipropylamino)propyl]pyridin-2-yl]phenyl]methyl]isoindole-1,3-dione Chemical compound CCCN(CCC)CCCC1=CC=CC(C=2C=CC(CN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=N1 GSRCVVJYCDYXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- OFVVJRNJCTZGJC-UHFFFAOYSA-N 2-chloro-6-(4-methylphenyl)pyridine Chemical compound C1=CC(C)=CC=C1C1=CC=CC(Cl)=N1 OFVVJRNJCTZGJC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ALPCQNPWUVQMHG-UHFFFAOYSA-N 2-propyl-3h-benzimidazole-5-carbonitrile Chemical compound C1=C(C#N)C=C2NC(CCC)=NC2=C1 ALPCQNPWUVQMHG-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BYDYILQCRDXHLB-UHFFFAOYSA-N 3,5-dimethylpyridine-2-carbaldehyde Chemical compound CC1=CN=C(C=O)C(C)=C1 BYDYILQCRDXHLB-UHFFFAOYSA-N 0.000 description 1
- ADKPPUWXHQFIAG-UHFFFAOYSA-N 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]-n-ethylpropanamide Chemical compound C1=CC(CN(CCC(=O)NCC)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ADKPPUWXHQFIAG-UHFFFAOYSA-N 0.000 description 1
- PNPSCHPKGJGSKJ-UHFFFAOYSA-N 3-[5-bromo-1-(methoxymethoxy)-2,3-dihydro-1H-inden-2-yl]butanal Chemical compound BrC1=CC=C2C(OCOC)C(C(C)CC=O)CC2=C1 PNPSCHPKGJGSKJ-UHFFFAOYSA-N 0.000 description 1
- XEIVJRDZIBTFNG-UHFFFAOYSA-N 3-[6-[4-(aminomethyl)phenyl]pyridin-2-yl]-n,n-dipropylpropan-1-amine Chemical compound CCCN(CCC)CCCC1=CC=CC(C=2C=CC(CN)=CC=2)=N1 XEIVJRDZIBTFNG-UHFFFAOYSA-N 0.000 description 1
- DPOZIJSMTCFUMK-UHFFFAOYSA-N 3-benzyl-2-[4-(dipropylamino)butyl]benzimidazole-5-carbaldehyde Chemical compound CCCN(CCC)CCCCC1=NC2=CC=C(C=O)C=C2N1CC1=CC=CC=C1 DPOZIJSMTCFUMK-UHFFFAOYSA-N 0.000 description 1
- JJOHTCGOQWVRSN-UHFFFAOYSA-N 4-(aminomethyl)-n-[4-(dipropylamino)butyl]benzamide Chemical compound CCCN(CCC)CCCCNC(=O)C1=CC=C(CN)C=C1 JJOHTCGOQWVRSN-UHFFFAOYSA-N 0.000 description 1
- BIRMZPRIYLJEGA-UHFFFAOYSA-N 4-(aminomethyl)-n-[4-[(dipropylamino)methyl]phenyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C1=CC=C(CN)C=C1 BIRMZPRIYLJEGA-UHFFFAOYSA-N 0.000 description 1
- PWSHUCWQUXJJHK-UHFFFAOYSA-N 4-[(1,3-dioxoisoindol-2-yl)methyl]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O PWSHUCWQUXJJHK-UHFFFAOYSA-N 0.000 description 1
- KHELOHWCQVWTSY-UHFFFAOYSA-N 4-[(dipropylazaniumyl)methyl]benzoate Chemical compound CCCN(CCC)CC1=CC=C(C(O)=O)C=C1 KHELOHWCQVWTSY-UHFFFAOYSA-N 0.000 description 1
- ZAFGEIQCLIDMKZ-UHFFFAOYSA-N 4-[5-(aminomethyl)-1-(methoxymethoxy)-2,3-dihydro-1h-inden-2-yl]-n,n-dipropylbutan-2-amine Chemical compound NCC1=CC=C2C(OCOC)C(CCC(C)N(CCC)CCC)CC2=C1 ZAFGEIQCLIDMKZ-UHFFFAOYSA-N 0.000 description 1
- WLXZAAORQAHVAA-UHFFFAOYSA-N 4-[5-bromo-1-(methoxymethoxy)-2,3-dihydro-1h-inden-2-yl]-n,n-dipropylbutan-2-amine Chemical compound BrC1=CC=C2C(OCOC)C(CCC(C)N(CCC)CCC)CC2=C1 WLXZAAORQAHVAA-UHFFFAOYSA-N 0.000 description 1
- DGVQQQQXIMISSH-UHFFFAOYSA-N 4-[6-(aminomethyl)-1h-inden-2-yl]-n,n-dipropylbutan-1-amine Chemical compound C1=C(CN)C=C2CC(CCCCN(CCC)CCC)=CC2=C1 DGVQQQQXIMISSH-UHFFFAOYSA-N 0.000 description 1
- SDLVSCGFIAWUBM-UHFFFAOYSA-N 4-[[(3,5-dimethylpyridin-2-yl)methyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]-n-[4-[(dipropylamino)methyl]phenyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CN(CC=1C(=CC(C)=CN=1)C)CC1=NC=CN1C SDLVSCGFIAWUBM-UHFFFAOYSA-N 0.000 description 1
- FIGNMIFTOBCQOY-UHFFFAOYSA-N 4-[tert-butyl(diphenyl)silyl]oxybutanal Chemical compound C=1C=CC=CC=1[Si](OCCCC=O)(C(C)(C)C)C1=CC=CC=C1 FIGNMIFTOBCQOY-UHFFFAOYSA-N 0.000 description 1
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- ABCGRFHYOYXEJV-UHFFFAOYSA-N 4-methylisoindole-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)NC2=O ABCGRFHYOYXEJV-UHFFFAOYSA-N 0.000 description 1
- NTSLROIKFLNUIJ-UHFFFAOYSA-N 5-Ethyl-2-methylpyridine Chemical compound CCC1=CC=C(C)N=C1 NTSLROIKFLNUIJ-UHFFFAOYSA-N 0.000 description 1
- CBYRBOFCUQZHAQ-UHFFFAOYSA-N 5-bromo-2-[4-[tert-butyl(diphenyl)silyl]oxybutyl]-2,3-dihydro-1h-inden-1-ol Chemical compound C1C2=CC(Br)=CC=C2C(O)C1CCCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 CBYRBOFCUQZHAQ-UHFFFAOYSA-N 0.000 description 1
- YRSCPVHPFVTDKG-UHFFFAOYSA-N 5-bromo-2-[4-[tert-butyl(diphenyl)silyl]oxybutyl]-2,3-dihydroinden-1-one Chemical compound C1C2=CC(Br)=CC=C2C(=O)C1CCCCO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 YRSCPVHPFVTDKG-UHFFFAOYSA-N 0.000 description 1
- KNCHDRLWPAKSII-UHFFFAOYSA-N 5-ethyl-2-methylpyridine Natural products CCC1=CC=NC(C)=C1 KNCHDRLWPAKSII-UHFFFAOYSA-N 0.000 description 1
- PPUYLXOFOVDYKU-UHFFFAOYSA-N 5-ethylpyridine-2-carbaldehyde Chemical compound CCC1=CC=C(C=O)N=C1 PPUYLXOFOVDYKU-UHFFFAOYSA-N 0.000 description 1
- SARODJOLCPBJHK-UHFFFAOYSA-N 5-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=C(C=O)N=C1 SARODJOLCPBJHK-UHFFFAOYSA-N 0.000 description 1
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- BMNPVMQSUPTGFD-UHFFFAOYSA-N 6-aminopyridine-3-carbaldehyde Chemical compound NC1=CC=C(C=O)C=N1 BMNPVMQSUPTGFD-UHFFFAOYSA-N 0.000 description 1
- FQPKKECSRKYXIZ-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=CC(Br)=CC=C21 FQPKKECSRKYXIZ-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 108050005711 C Chemokine Proteins 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- NIZYZWDYTODUKJ-UHFFFAOYSA-N C(CC)N(CCCCNC(=O)C=1N=C2N(C=CC=C2)C1)CCC Chemical compound C(CC)N(CCCCNC(=O)C=1N=C2N(C=CC=C2)C1)CCC NIZYZWDYTODUKJ-UHFFFAOYSA-N 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- MZWSXHMPIXXNBS-UHFFFAOYSA-N CCCN(CCC)CCCCNCC1=CC=C(C=C1)CN2C=C3C=CC=CC3=C2 Chemical compound CCCN(CCC)CCCCNCC1=CC=C(C=C1)CN2C=C3C=CC=CC3=C2 MZWSXHMPIXXNBS-UHFFFAOYSA-N 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- HCVBQXINVUFVCE-UHFFFAOYSA-N Citronensaeure-beta-methylester Natural products COC(=O)C(O)(CC(O)=O)CC(O)=O HCVBQXINVUFVCE-UHFFFAOYSA-N 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- KMHZPJNVPCAUMN-UHFFFAOYSA-N Erbon Chemical compound CC(Cl)(Cl)C(=O)OCCOC1=CC(Cl)=C(Cl)C=C1Cl KMHZPJNVPCAUMN-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ATFVTAOSZBVGHC-UHFFFAOYSA-N Glycolaldehyde dimer Chemical compound OC1COC(O)CO1 ATFVTAOSZBVGHC-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 108010056642 N-alpha-acetyl-nona-D-arginine amide acetate Proteins 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- NWMJYSFKQUFWON-UHFFFAOYSA-N N1C(=NC=C1)CN(CC=1N(C=CN1)C)CC=1C=CC2=C(N(C=N2)C)C1 Chemical compound N1C(=NC=C1)CN(CC=1N(C=CN1)C)CC=1C=CC2=C(N(C=N2)C)C1 NWMJYSFKQUFWON-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 239000005922 Phosphane Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HJPOKQICBCJGHE-UHFFFAOYSA-J [C+4].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [C+4].[Cl-].[Cl-].[Cl-].[Cl-] HJPOKQICBCJGHE-UHFFFAOYSA-J 0.000 description 1
- WGPAQYSVWYWZKT-UHFFFAOYSA-N [C].[Ra] Chemical compound [C].[Ra] WGPAQYSVWYWZKT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical group C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- ZPFKRQXYKULZKP-UHFFFAOYSA-N butylidene Chemical group [CH2+]CC[CH-] ZPFKRQXYKULZKP-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- CSYOORDPNRFQTI-UHFFFAOYSA-N dimethyl 3-methylbenzene-1,2-dicarboxylate Chemical compound COC(=O)C1=CC=CC(C)=C1C(=O)OC CSYOORDPNRFQTI-UHFFFAOYSA-N 0.000 description 1
- SJOMVAHCMAQIDI-UHFFFAOYSA-N dimethyl 4-[(1,3-dioxoisoindol-2-yl)methyl]benzene-1,2-dicarboxylate Chemical compound C1=C(C(=O)OC)C(C(=O)OC)=CC=C1CN1C(=O)C2=CC=CC=C2C1=O SJOMVAHCMAQIDI-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 1
- PTSANERYNRBJAI-UHFFFAOYSA-N ethyl 2-[[4-(dipropylamino)butyl-methylamino]methyl]-5-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]benzoate Chemical compound C1=C(C(=O)OCC)C(CN(C)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 PTSANERYNRBJAI-UHFFFAOYSA-N 0.000 description 1
- ODCVKVWYZDDQBS-UHFFFAOYSA-N ethyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OCC)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ODCVKVWYZDDQBS-UHFFFAOYSA-N 0.000 description 1
- XIFMXUFFSMVWJS-UHFFFAOYSA-N ethyl 6-formylimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=C(C=O)C=CC2=NC(C(=O)OCC)=CN21 XIFMXUFFSMVWJS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- LRJOKNYELSECDZ-UHFFFAOYSA-N imidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=C(C#N)C=CC2=NC=CN21 LRJOKNYELSECDZ-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- DWAIWJVUOIWGLB-UHFFFAOYSA-N methyl 2-(4-aminobutyl)-3-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N=C(CCCCN)N(C)C2=C1 DWAIWJVUOIWGLB-UHFFFAOYSA-N 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- KDWWRPVLCYMLRN-UHFFFAOYSA-N methyl 2-[4-(dipropylamino)butyl]-3h-benzimidazole-5-carboxylate Chemical compound C1=C(C(=O)OC)C=C2NC(CCCCN(CCC)CCC)=NC2=C1 KDWWRPVLCYMLRN-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- YMSOSOMMYUWVAA-UHFFFAOYSA-N methyl 3-[1-(4-aminophenyl)ethyl-[4-(dipropylamino)butyl]amino]propanoate Chemical compound CCCN(CCC)CCCCN(CCC(=O)OC)C(C)C1=CC=C(N)C=C1 YMSOSOMMYUWVAA-UHFFFAOYSA-N 0.000 description 1
- CYRLNYXWQXTHTL-UHFFFAOYSA-N methyl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OC)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 CYRLNYXWQXTHTL-UHFFFAOYSA-N 0.000 description 1
- GIZCKBSSWNIUMZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C(CN)C=C1 GIZCKBSSWNIUMZ-UHFFFAOYSA-N 0.000 description 1
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
- UDPLKASYJHMKIP-UHFFFAOYSA-N methyl 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoate Chemical compound COC(=O)C1=CC=C(CNC(=O)OC(C)(C)C)C=C1 UDPLKASYJHMKIP-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- SUKHYAQMHYSZPA-UHFFFAOYSA-N n-(1h-imidazol-2-ylmethyl)-n-[(1-methylimidazol-2-yl)methyl]-1-[2-(4-piperidin-1-ylbutyl)-3-propylbenzimidazol-5-yl]methanamine Chemical compound N=1C2=CC=C(CN(CC=3NC=CN=3)CC=3N(C=CN=3)C)C=C2N(CCC)C=1CCCCN1CCCCC1 SUKHYAQMHYSZPA-UHFFFAOYSA-N 0.000 description 1
- YUZGGAYYSZILCI-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methylbenzenecarbothioamide Chemical compound C1=CC(C)=CC=C1C(=S)NC1=CC=C(C#N)C=C1 YUZGGAYYSZILCI-UHFFFAOYSA-N 0.000 description 1
- ULMCRMBBHZMIKA-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-2,2,2-trifluoro-n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]acetamide Chemical compound C1=CC(CN(CCCCN(CCC)CCC)C(=O)C(F)(F)F)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 ULMCRMBBHZMIKA-UHFFFAOYSA-N 0.000 description 1
- IACQEISMUOGDDK-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-4-[[(1-methylimidazol-2-yl)methylamino]methyl]benzamide Chemical compound C1=CC(C(=O)NCCCCN(CCC)CCC)=CC=C1CNCC1=NC=CN1C IACQEISMUOGDDK-UHFFFAOYSA-N 0.000 description 1
- FKKIVKBWYCQZJQ-UHFFFAOYSA-N n-[4-(dipropylamino)butyl]-n-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]acetamide Chemical compound C1=CC(CN(CCCCN(CCC)CCC)C(C)=O)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 FKKIVKBWYCQZJQ-UHFFFAOYSA-N 0.000 description 1
- ASTCREPTOKSIFR-UHFFFAOYSA-N n-[4-[(dipropylamino)methyl]phenyl]-4-[[(1-methylimidazol-2-yl)methylamino]methyl]benzamide Chemical compound C1=CC(CN(CCC)CCC)=CC=C1NC(=O)C(C=C1)=CC=C1CNCC1=NC=CN1C ASTCREPTOKSIFR-UHFFFAOYSA-N 0.000 description 1
- UBRJGFJCEURHDH-UHFFFAOYSA-N n-[[2-[4-(dipropylamino)butyl]-1-oxo-3h-isoindol-5-yl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=C2C(=O)N(CCCCN(CCC)CCC)CC2=C1 UBRJGFJCEURHDH-UHFFFAOYSA-N 0.000 description 1
- DYKADEJKBFDDRU-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-n-methyl-4-piperidin-1-ylbutan-1-amine Chemical compound C=1C=C(CN)C=CC=1CN(C)CCCCN1CCCCC1 DYKADEJKBFDDRU-UHFFFAOYSA-N 0.000 description 1
- WPPCCGBCIIMDHR-UHFFFAOYSA-N n-[[4-[(1h-imidazol-2-ylmethylamino)methyl]phenyl]methyl]-n-methyl-4-piperidin-1-ylbutan-1-amine Chemical compound C=1C=C(CNCC=2NC=CN=2)C=CC=1CN(C)CCCCN1CCCCC1 WPPCCGBCIIMDHR-UHFFFAOYSA-N 0.000 description 1
- DSILTDWFQVMLRG-UHFFFAOYSA-N n-[[4-[6-(aminomethyl)-1-methylbenzimidazol-2-yl]phenyl]methyl]-n-propylpropan-1-amine Chemical compound C1=CC(CN(CCC)CCC)=CC=C1C1=NC2=CC=C(CN)C=C2N1C DSILTDWFQVMLRG-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BBNYLDSWVXSNOQ-UHFFFAOYSA-N oxolane-2-carbaldehyde Chemical group O=CC1CCCO1 BBNYLDSWVXSNOQ-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 150000002969 pentanoic acid esters Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910000064 phosphane Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XCPUHNKTFPDFOQ-UHFFFAOYSA-N propan-2-yl 3-[4-(dipropylamino)butyl-[[4-[[1h-imidazol-2-ylmethyl-[(1-methylimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]propanoate Chemical compound C1=CC(CN(CCC(=O)OC(C)C)CCCCN(CCC)CCC)=CC=C1CN(CC=1N(C=CN=1)C)CC1=NC=CN1 XCPUHNKTFPDFOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- FDNAPBUWERUEDA-UHFFFAOYSA-N silicon tetrachloride Chemical compound Cl[Si](Cl)(Cl)Cl FDNAPBUWERUEDA-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
- C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to an Aminyi conjugate, a pharmacologically acceptable salt thereof, or a prodrug thereof, and particularly to an Aminyi conjugate having an antiviral activity based on an antagonistic effect on a chemokine receptor CXCR4. Further, the present invention relates to a drug for a related disease such as rheumatic disease or cancer metastasis disease based on the antagonistic action on the chemokine receptor CXCR4, using these compounds as active ingredients.
- Non-Patent Document 1 There are two reverse transcriptase inhibitors and protease inhibitors for the treatment of acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) infection, but the emergence of drug-resistant HIV mutants is treated. The effect is lost (for example, see Non-Patent Document 1).
- the combination therapy of these combinations also has many complicated conditions to be taken when taking them, has a large number to be taken, and has various side effects (for example, see Non-Patent Document 2).
- protease inhibitors in particular, despite the complicated oral administration method and the large number of side effects, it is known that the possibility of causing the emergence and selection of resistant strains increases unless the drug is maintained at almost 100%. (For example, see Non-Patent Document 3).
- chemokines those that show chemotaxis to leukocytes are called chemokines, which are secreted proteins.
- CXCR4 a ligand of CXC—chemokine SDF-1 ⁇ , is used as a receptor when ⁇ cell-directed HIV is transmitted to host cells.
- CXCR4 has been clearly linked to various diseases other than HIV infection.
- rheumatic diseases for example, see Patent Document 1
- cancer metastases for example, see Non-Patent Document 10.
- Patent Document 1 WO 00/06086 pamphlet
- Non-Patent Document 1 Latest Medicine, Vol. 53, No. 9, pp. 2031 (1998)
- Non-patent document 2 Nikkei Science, October issue, p. 29 (1998)
- Non-Patent Document 3 Molecular Medicine, Vol. 36, No. 9, p. 1012 (1999)
- Non-Patent Document 4 Nikkei Science, October, p. 42 (1998)
- Non-Patent Document 5 Science, 272, 872 (1996)
- Non-Patent Document 6 Nature, 382, 829 (1996)
- Non-patent document 10 Nature, 410, 50 (2001) Disclosure of the invention
- An object of the present invention is to provide a highly safe drug having a novel chemical structure, which has an excellent antiretroviral effect, has an excellent CXCR4 antagonistic effect on SDF-1a, and has a high chemical safety. It is where drugs are offered.
- An object of the present invention is to provide a compound represented by the following general formula (1) having the antiviral activity mainly of HIV and having CXCR4 antagonistic activity.
- the present invention provides a drug for treating a patient with a virulent virus and for treating a patient with rheumatism, cancer, or the like.
- the present invention relates to a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- n 0
- R, R, R, R, R, and R each independently represent a hydrogen atom, an optionally substituted carbon atom 1
- R and R represent a carbonyl group together with the carbon atom to which they are attached.
- a and A are each a hydrogen atom, an optionally substituted monocyclic or polycyclic
- the substituent may be a partially saturated polycyclic aromatic ring, a heterocyclic ring which may be substituted, or a group represented by the following formula (2).
- R, R, R, and R each independently represent a hydrogen atom, an optionally substituted
- Alkyl group an optionally substituted alkyl group having 2 to 15 carbon atoms, an optionally substituted alkyl group having 2 to 15 carbon atoms, or a substituted or unsubstituted alkyl group having 3 to 15 carbon atoms 15 cyclic alkyl groups are shown.
- W represents a benzene ring or a group represented by any of the following formulas (10) and (11), which may be substituted.
- R is a hydrogen atom, which may have 1 or less carbon atoms.
- n an integer of 0-2.
- T and T indicate CH or CO.
- X may be substituted ⁇ monocyclic or polycyclic heteroaromatic ring, may be substituted ⁇ monocyclic or polycyclic aromatic ring, 0, CH
- R is a hydrogen atom, an optionally substituted alkyl group having 1-15 carbon atoms, an optionally substituted
- an alkyl group having 2 to 15 carbon atoms, substituted! /, Or! / An alkyl group having 2 to 15 carbon atoms, or a substituted or unsubstituted, 3 to 15 carbon atoms Represents a cyclic alkyl group.
- R represents a carboxyl group or an alkoxycarbonyl group.
- T represents an oxygen atom or a sulfur atom.
- R and R represent a hydrogen atom and an alkyl group having 13 carbon atoms, and R and R are bonded to each other
- 31 32 31 32 may form a ring.
- D represents a group represented by the above formula (4) or the following formula (6).
- R is a hydrogen atom, an optionally substituted alkyl group having 11 to 15 carbon atoms, an optionally substituted
- V C 2-15 alkyl group, substituted! /, Or! /, C 2-15 alkyl group, or optionally substituted C 3-15 cyclic It represents an alkyl group or a group represented by the following formula (5).
- n an integer of 2—4.
- R, R, R and R are each independently a hydrogen atom, an optionally substituted carbon atom
- An alkyl group, an optionally substituted alkyl group having 2 to 15 carbon atoms, an optionally substituted V, an alkyl group having 2 to 15 carbon atoms, or a substituted or unsubstituted represents a cyclic alkyl group represented by Formula 3 to 15.
- Q is a single bond when X is 0, a single bond when X is NR, or
- X is a monocyclic or polycyclic heteroaromatic ring which may be substituted, a monocyclic or polycyclic aromatic ring which may be substituted, CH, or a group represented by the formula ( 3), when expressed by equation (12)
- R is a hydrogen atom, an optionally substituted alkyl group having 11 to 15 carbon atoms,
- an alkyl group having 2 to 15 carbon atoms substituted! /, Or! /, An alkyl group having 2 to 15 carbon atoms, or an optionally substituted 3 to 15 carbon atom
- R is an optionally substituted alkyl group having 11 to 15 carbon atoms, an optionally substituted carbon number
- Y represents a group represented by the following formula (7). [0022] [Formula 12]
- n an integer of 0-6.
- R and R are each independently a hydrogen atom or an optionally substituted alkyl
- m represents an integer of 02.
- R, R, R and R are each independently a hydrogen atom, an optionally substituted carbon atom
- Q represents S, 0, or NH; Q is S, 0, or NH;
- R and R are each independently a hydrogen atom or an optionally substituted alkyl
- R and R each independently represent a hydrogen atom when X is CH,
- a ring may be formed by bonding through an aromatic ring, a heteroaromatic ring, or a heterocyclic ring.
- R and R are each independently a hydrogen atom when X is not CH, by the following formula (9)
- a ring may be formed by bonding via a heteroatom, a cyclic alkyl group, an aromatic ring, a heteroaromatic ring, or a heterocycle.
- n 0 or 1
- Q CH or N
- Q is N, S, or 0,
- Q and Q each independently represent CH or N.
- G represents a substituted or unsubstituted alkylene group having 11 to 15 carbon atoms, or a substituted or unsubstituted alkylene group having 2 to 15 carbon atoms.
- R is the number of carbon atoms substituted at any position other than the nitrogen atom which may be present on the ring
- R represents a hydrogen atom or the same group as R, and may combine with G to form a ring.
- one or two or more asymmetric carbons that may be present in the compound represented by the general formula (1), in the case of one, a pure optically active compound represented by the absolute configuration R or S, A mixture, racemate, or, in the case of two or more, optically pure diastereomer, its racemate, or a combination thereof in any ratio exists in any ratio. Is also good.
- the terms used in this specification are defined as follows, and are used alone or in combination.
- the alkyl group is a saturated hydrocarbon group which may be linear, branched or cyclic, such as a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group and a pentyl group. And a neopentyl group.
- An alkenyl group is a hydrocarbon group having a double bond in any of a straight chain, a branched chain, and a ring, such as an aryl group, a 1-butenyl group, a 2-butenyl group, an isobutenyl group, a cyclohexenyl group, and the like. Is mentioned.
- the alkynyl group is a hydrocarbon group having a triple bond in any of linear, branched or cyclic, and examples thereof include a propynyl group and a 1-butynyl group.
- the cyclic alkyl group represents a cyclic hydrocarbon group, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and the like.
- the aromatic ring means an aromatic ring composed of a hydrocarbon, and when it is a monocyclic ring, a benzene ring, and when it is a polycyclic ring, for example, a naphthalene ring, an anthracene ring, and the like.
- Partially saturated polycyclic aromatic rings include, for example, dihydronaphthalene ring, tetralin ring, indane ring and the like.
- a heteroaromatic ring means an aromatic ring in which one or more of a nitrogen atom, an oxygen atom and a sulfur atom are contained in the ring, and when it is a single ring, for example, a pyrrole ring , A furan ring, a thiophene ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, an imidazole ring, a pyrazole ring, an oxazole ring, a thiazole ring, a thiadiazole ring, an oxadiazole ring, and a triazole ring.
- a quinoline ring for example, a quinoline ring, isoquinoline ring, benzimidazole ring, indazole ring, benzthiazole ring, benzoxazole ring, indole ring, benzfuran ring, benzthiophene ring and the like can be mentioned.
- heterocycle means a saturated ring which may contain one or more of nitrogen, oxygen and sulfur atoms in the ring, for example, piperidine, piperidine, piperazine, morpholine, Thiomorpholine and the like.
- alkylene group is a hydrocarbon group that connects two groups to terminals, for example, ethylene Group, propylene group, isopropylene group, butylene group, isobutylene group, 2,2-dimethylethylene group and the like.
- the alkylene group is a group having a double bond in the alkylene, and includes, for example, a probelene group, a 2-butylene group, a 1,3-butagelen group and the like.
- the alkylene group is a group having a triple bond in the alkylene group, and examples thereof include a propylene group and a butylene group.
- the acyl group is a group in which a hydrogen atom, an alkyl group, a monocyclic or polycyclic heteroaromatic ring, or a monocyclic or polycyclic aromatic ring is bonded via a carbonyl group.
- These groups may be substituted at any position, and examples thereof include a formyl group, an acetyl group, a benzoyl group and a trifluoroacetyl group.
- the ring formed together with the nitrogen atom to which they are bonded represents, for example, a pyrrolidine ring, a piperidine ring, a hexamethyleneimine ring, a heptamethyleneimine ring, etc.
- a ring together with the nitrogen atom in which case, for example, represents a morpholine ring, a piperazine ring, etc., and forms a ring via an aromatic ring.
- examples thereof include a tetrahydroisoquinoline ring and a tetrahydroindole ring.
- R or Z and R are groups represented by the above formula (8), and R and G form a ring.
- R and R are, for example, a tetralinyl group, an indanyl group, a tetrahydroquino group.
- substituted or substituted in the expression of each substituent means a hydroxyl group, a thiol group, a formyl group, a carboxyl group, a sulfol group, an amino group, an amide group, a carbamoyl group, a cyano group.
- the alkoxy group may be substituted through an oxygen atom, an alkyl group, a cyclohexyl group
- an acylamino group indicates that an alkyl group or a phenyl group is bonded to an amino group via a carboxy group
- an acyloxy group indicates that an alkyl group is a carboxy group
- an alkoxycarbonyl group represents that an alkoxy group is bonded to an oxygen atom through a carboxy group.
- a prodrug is a precursor substance that becomes an effective drug by being chemically or biochemically metabolized after being administered to a living body, and is a cyclic ring such as a heterocyclic ring contained in the compound represented by the general formula (1).
- Compounds in which one or more groups, such as an alkoxycarbonyl group, a dialkylaminosulfone group, etc., which are metabolized and eliminated in the living body, are bonded to the medium N or chain N, and are represented by the general formula (1). It represents a compound in which at least one ester group, amide group or the like utilizing an alcohol or a carboxylic acid, which may be contained in the compound shown, is bonded.
- Pharmaceutically acceptable salts include, for example, trifluoroacetate, hydrochloride, acetate, sulfate, nitrate, lactate, maleate, methanesulfonate, toluenesulfonate, tartaric acid Salt, citrate, oxalate, malonate, succinate, fumarate, propionate, butyrate, glucuronic acid, terephthalic acid, phosphoric acid and the like can be mentioned.
- hydrochloride, maleate, tartrate, citrate, and more preferably tartrate can be mentioned.
- the present invention relates to a CXCR4 antagonist comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the CXCR4 antagonist or a salt thereof according to the present invention is used for the treatment or prevention of a viral disease, for example, AIDS, or for the treatment of cancer, or for the treatment or prevention of rheumatism or the like.
- the pharmacologically acceptable salt is any one that is capable of forming a salt with the aminy conjugate shown by the above formula (1) and is pharmacologically acceptable. May be.
- trifluoroacetate, hydrochloride, acetate, sulfate, nitrate, lactate, maleate, methanesulfonate, toluenesulfonate, tartrate, citrate, oxalate, malonate examples include succinate, fumarate, propionate, butyrate, glucuronic acid, terephthalic acid, and phosphoric acid.
- a hydrochloride, a maleate, a tartrate, a taenoate, and more preferably a tartrate can be mentioned.
- these compounds may optionally form a hydrate or a solvate.
- one or more asymmetric carbon atoms which may be present in the compound represented by the general formula (1)
- pure optics represented by the absolute configuration R or S The active substance, a mixture of any ratio thereof, a racemate, and in the case of two or more, an optically pure diastereomer, a racemate thereof, or a combination thereof in any ratio may be present. You may.
- compositions comprising the compound of the present invention represented by the general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient are usually prepared as pharmacologically acceptable carriers and excipients known per se.
- Excipients, diluents, extenders, disintegrants, stabilizers, preservatives, buffers, emulsifiers, fragrances, coloring agents, sweeteners, thickeners, corrigents, solubilizers, other additives specifically Are water, vegetable oils, alcohols such as ethanol or benzyl alcohol, glycols, carbohydrates such as glycerol triacetate, gelatin, ratatose, starch, magnesium stearate, potassium stearate, talc, lanolin, vaseline, macrogol, Tablets, powders, granules, capsules, pills, suppositories, injections, eye drops, liquids, troches are prepared by mixing microcrystalline cellulose, hydroxypropylcellulose, etc.
- the dosage may vary depending on the type and severity of the disease, the compound to be administered and the route of administration, the age, sex, and weight of the patient.For oral administration, it is usual to administer 0.1 to 5000 mg, especially 11 to 3000 mg, per adult. preferable. In the case of a prodrug, it is particularly preferable to administer 11 to 5000 mg.
- novel aminy conjugate or a pharmacologically acceptable salt thereof or a prodrug thereof according to the present invention can provide a novel CXCR4 antagonist.
- the novel CXCR4 antagonist of the present invention has a CXCR4 antagonistic effect, and is excellent as a therapeutic or prophylactic agent for diseases such as HIV infection, rheumatism, or cancer metastasis based on the CXCR4 antagonistic activity. Is shown.
- Example 1 2-[(4-dipropylamino-butyl)-(4- ⁇ [(1 ⁇ -imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino]- Synthesis of methyl ⁇ -benzyl) -amino] -ethanol [Compound No. 1]
- Example 1-1 4- (1,3-Dioxo-1,3-dihydro-isoindole-2-ylmethyl) -benzaldehyde Synthesis of
- the solution was concentrated to dryness and dried, and then 4.0 ml of methanol and 4.0 ml of a 4 mol / l hydrogen chloride / dioxane solution were added, followed by stirring at room temperature for 2 hours. After completion of the reaction, the solvent was distilled off, and then dioxane was added to wash the residue to obtain 654 mg of the hydrochloride of the title compound.
- Example 1-1 103 mg of the compound obtained in Example 1-1 was dissolved in 10 ml of anhydrous methanol, and 114 mg of the hydrochloride of the compound obtained in Example 2 was added. 0.108 ml of triethylamine and 3 g of anhydrous magnesium sulfate were added thereto, and the mixture was stirred at room temperature for 1 hour. Anhydrous magnesium sulfate was removed by filtration through Celite, methanol was distilled off, and the mixture was dried with a vacuum pump. This was dissolved in 10 ml of anhydrous methanol, and 22.0 mg of sodium borohydride was gradually added under ice-cooling. This was returned to room temperature and stirred for 1 hour.
- Example 1-3 60.3 mg of the compound obtained in Example 1-3 was dissolved in chloroform, and 47.0 mg of di-t-butyl dicarbonate was added thereto. After stirring at room temperature for 30 minutes, the mixture was concentrated, and purified by silica gel column chromatography (chloroform / methanol) to obtain 70.0 mg of the title compound as a colorless viscous liquid.
- Example 1-6 Synthesis of (4-dipropylamino-butyl)-(4- ⁇ [(1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -benzyl) -hexarubamic acid-1-butyl ester
- Example 1-5 0.78 g of the compound obtained in Example 1-5 was dissolved in 20 ml of methanol, 214 mg of 2-imidazole carboxyaldehyde was added, and the mixture was stirred at room temperature for 17 hours. After the solvent was distilled off, the residue was vacuum-dried, dissolved in methanol (15 ml), sodium borohydride (217.8 mg) was added, and the mixture was stirred at room temperature for 45 minutes. 10 ml of a saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was stirred at room temperature for 15 minutes.
- Example 1-7 (4-dipropylamino-butyl)-(4- ⁇ [(1 ⁇ -imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ - Synthesis of t-butyl ester of benzyl) -hydroxylbamate
- Example 1-6 231 mg of the compound obtained in Example 1-6 was dissolved in 5.0 ml of anhydrous methanol, and 61.6 mg of sodium cyanoborohydride, 2.00 ml of acetic acid and 80.9 mg of 1-methyl-2-imidazolecarboxaldehyde were added, and the mixture was added at room temperature under a nitrogen atmosphere. For 6 days. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, a saturated aqueous solution of sodium hydrogen carbonate was added, and the mixture was stirred for a while. This was extracted with chloroform, washed with a saturated aqueous solution of sodium hydrogen carbonate and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (chloroform / methanol / water) to obtain 197 mg of the title compound as a colorless oil.
- Example 1-8 N- (4- ⁇ [(1H-imidazole-2-ylmethyl)-(1-methyl-1H-imidazole) -2-ylmethyl) -amino] -methyl ⁇ -benzyl) -Synthesis of - ⁇ ,, ⁇ , -dipropylbutane-1,4-diamine 197 mg of the compound obtained in Example 1-7 was dissolved in 1.0 ml of methanol. Then, 3.0 ml of a 10% salt / hydrogen / methanol solution was added, and the mixture was stirred at room temperature overnight. After completion of the reaction, the solvent was distilled off to obtain 159 mg of the hydrochloride of the title compound as a white solid.
- Example 2-3 113 mg of the compound obtained in Example 2-3 was dissolved in 2.0 ml of DMF, and potassium phthalimide was dissolved. 69.0 mg was added and the mixture was stirred at room temperature for 2 days. After completion of the reaction, the solvent was distilled off under reduced pressure, and the residue was dissolved in chloroform and washed with water. After extraction with chloroform, the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was dried under vacuum. The residue was dissolved in 1.5 ml of a 40% methylamine / methanol solution and stirred at room temperature for 1 hour.
- the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, and washed with water and an aqueous solution of lmol / 1 sodium hydroxide. After extraction with black hole form, the extract was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform / methanol) to obtain 39.8 mg of the title compound as a brown solid.
- Example 2-4 39.8 mg of the compound obtained in Example 2-4 was dissolved in 1.0 ml of methanol, and 13.3 mg of 2-imidazole carboxyaldehyde and 0.030 ml of trimethyl orthoformate were added and stirred at room temperature for 30 minutes. To this, 10.5 mg of sodium borohydride was added little by little, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with water and extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure.
- Example 6-1 Synthesis of 4- ⁇ [t-butoxycarbol- (1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -benzoic acid
- the solvent was distilled off, the residue was dissolved in chloroform and washed with saturated saline. After drying over anhydrous sodium sulfate, the solvent was distilled off, and 43 ml of THF, 43 ml of methanol and 43 ml of an aqueous solution of lmol / 1 sodium hydroxide were added, followed by stirring at room temperature for 14 hours. After completion of the reaction, the solvent was distilled off, 5.0 ml of water was added, and carefully cautiously added with 1 mol / 1 hydrochloric acid, and the acid precipitate was collected by filtration and dried to obtain 4.87 g of the title compound as a white solid.
- Tsu set (set x—one, 81,):
- Example 7-2 Synthesis of dimethyl 4- (1,3-dioxo-1,3-dihydro-isoindole-2-ylmethyl) -phthalate
- Example 7-1 202 mg of the compound obtained in Example 7-1 was dissolved in 7.1 ml of tetrachloride carbon, and 205 mg of N-bromosuccinimide and 15.8 mg of 2,2, -azobisisobutymouth-tolyl were heated and refluxed for 20 hours. did. 7.0 ml of Shishio-Danicarbon and 51.3 mg of N-bromosuccinimide were added, and the mixture was further heated and refluxed for 4 hours. After allowing to cool, water was added to stop the reaction, followed by extraction with black-mouthed form. The organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate.
- Example 7-3 4- (t-butoxycarbol-amino) Synthesis of dimethyl (methyl) -phthalate
- Example 7-5 86.5 mg of the compound obtained in Example 7-5 was dissolved in 2.0 ml of acetic acid and heated to 60 ° C. 130 mg of zinc powder was added to this solution in several portions, and the mixture was heated to reflux for 10 hours. After allowing to cool to room temperature, the solution was filtered through celite, concentrated under reduced pressure, neutralized with a saturated aqueous solution of sodium hydrogen carbonate, and extracted with chloroform. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated saline, and then dried over anhydrous sodium sulfate. Evaporation of the solvent gave 66.lmg of a mixture of the title compounds as a yellow oil.
- Example 7-7 2- (4-dipropylamino-butyl) -5- ⁇ [(1 ⁇ -Imidazole-2-ylmethyl) -amino] -methyl ⁇ -2,3-dihydro-isoindol-1-one
- Example 7-8 2- (4-dipropylamino-butyl) -5- ⁇ [(1 ⁇ - Synthesis of imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -2,3-dihydro-isoindole-1-one
- Example 7-7 20.3 mg of the compound obtained in Example 7-7 was dissolved in 2.0 ml of methanol, and 1-methyl-2-imidazolecarboxaldehyde was dissolved.
- Example 8 2- (4-dipropylamino-butyl) -6- ⁇ [(1 ⁇ -imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -2 Of 1,3-dihydro-isoindole-1-one
- Example 8-1 2- (4-Dipropylamino-butyl) -6- ⁇ [(1 ⁇ -imidazole-2-ylmethyl) -amino] -methyl ⁇ -2,3-dihydro-isoindol-1-one Synthesis
- Example 7-6 To 66.1 mg of the compound obtained in Example 7-6, lmol / 1 hydrochloric acid was added, and the mixture was heated under reflux for 18 hours. The concentrated residue was dissolved in methanol, and the pH was adjusted to 8 by adding an anion exchange resin (Amberley HRA-410). The resin was separated by filtration, the residue obtained by evaporating the solvent of the filtrate was dissolved in 2.0 ml of methanol, and 0.070 ml of trimethyl orthoformate and 28.8 mg of 2-imidazolecarboxaldehyde were added. The mixture was stirred at room temperature for 20 hours. After the solution was cooled to 0 ° C., 22.7 mg of sodium borohydride was added, and the mixture was heated to room temperature and stirred for 3 hours. Water was added to stop the reaction, and the mixture was extracted with chlorophonolem.
- an anion exchange resin Amberley HRA-410
- Example 8-2 2- (4-dipropylamino-butyl) -6- ⁇ [(1 ⁇ - Synthesis of imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -2,3-dihydro-isoindole-1-one
- Example 8-1 15.1 mg of the compound obtained in Example 8-1 was dissolved in 1.5 ml of methanol, 5.0 mg of 1-methyl-2-imidazolecarboxaldehyde and 4.8 mg of sodium cyanoborohydride were added, and the pH was adjusted with acetic acid. It was adjusted to 4 and stirred at room temperature for 2.5 hours. The reaction was stopped by adding a saturated aqueous solution of sodium hydrogencarbonate, and the mixture was extracted with chloroform. The organic layer was washed with water and saturated saline, and dried with anhydrous sodium sulfate.
- Example 10-1 56.1 g of the compound obtained in Example 10-1 was added little by little under ice-cooling to 119 ml of Shio-Dai-Thionyl. After the addition, the mixture was refluxed at 65 ° C for 15 minutes. Excess chloride salt was distilled off under reduced pressure and azeotropic distillation with toluene to obtain 82.4 g of the hydrochloride of the title compound as a yellow solid.
- Example 10-3 N-methyl- ⁇ - [4-( ⁇ [1- (1-methyl-1H-imidazole-2-ylmethyl) -1H-imidazole-2-ylmethyl] amino ⁇ -methyl ) Synthesis of -benzyl-N,, ⁇ ⁇ ⁇ ⁇ , -dipropylbutane-1,4-diamine [diagonal compound No.10]
- Example 11-1 6.56 g of the compound obtained in Example 11-1 was dissolved in 262 ml of dichloromethane. For 2 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (3.86 g) as a colorless oil.
- Example 11-4 2.03 g of the compound obtained in Example 11-4 was dissolved in 61 ml of methanol and 31 ml of THF, and 0.442 g of sodium borohydride was added under ice-cooling, followed by stirring at room temperature for 2 hours. To the reaction solution was added a saturated aqueous solution of ammonium chloride, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane / ethyl acetate) to obtain 1.54 g of the title compound as a yellow oil.
- Example 11-6 Synthesis of [4- (5-bromo-1-methoxymethoxy-1-indan-2-yl) -butoxy] -t-butyldifluorosilane
- Example 11-8 Synthesis of 5-bromo-2- (3-dipropylaminobutyl) -1-methoxymethoxy-indane
- Example 11-7 574.0 mg of the compound obtained in Example 11-7 was dissolved in 28.7 ml of 1,2-dichloroethane, and under room temperature stirring, 266.3 mg of di-n-propylamine and 743.6 mg of sodium triacetoxyborohydride were added. Stirred for 20 hours. An lmol / 1 sodium hydroxide aqueous solution was added to the reaction mixture, extracted with chloroform, and the organic layer was washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (form: form / methanol) to obtain 552.4 mg of the title compound as a yellow oil.
- Example 11-8 552 mg of the compound obtained in Example 11-8 was dissolved in 1.67 ml of DMF, 94.3 mg of zinc cyanide and 61.8 mg of tetrakistriphenylphosphine palladium were added, and the mixture was stirred at 80 ° C. for 48 hours.
- the reaction solution was washed with 7% aqueous ammonia and saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (chloroform / methanol) to give the title compound (436.8 mg) as a yellow oil.
- Example 11-9 436 mg of the compound obtained in Example 11-9 was dissolved in 21.8 ml of THF, 138.7 mg of lithium aluminum hydride was added, and the mixture was stirred at room temperature for 24 hours. Ethyl acetate, methanol, and a 10% aqueous solution of sodium potassium tartrate were added to the reaction solution and stirred for 1 hour. The extract was extracted with black hole form, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform / ethyl acetate) to give the title compound.
- Example 11-11 2- [2- (4-dipropylaminobutyl) -1-methoxymethoxy-indan-5-yl Synthesis of [Methyl] -isoindole-1,3-dione
- Example 11-11 113.0 mg of the compound obtained in Example 11-11 was dissolved in 2.2 ml of dioxane, and the mixture was stirred at room temperature for 24 hours.
- the reaction solution was concentrated under reduced pressure as it was, the residue was dissolved in chloroform, washed with aqueous sodium hydrogencarbonate solution, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (form: form / methanol) to obtain 98.8 mg of the title compound as a yellow oil.
- Example 11-13 40.1 mg of the compound obtained in Example 11-13 was dissolved in 2.0 ml of methanol, and 19.2 mg of 2-imidazolecarboxaldehyde and 42.5 mg of trimethyl orthoformate were added, followed by stirring at room temperature for 30 minutes. Subsequently, under ice-cooling, 15.1 mg of sodium borohydride was added and stirred at room temperature for further 30 minutes. The reaction solution was concentrated under reduced pressure as it was, water was added to the residue, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform / methanol) to give the title compound (27.3 mg) as a yellow oil.
- Example 12-1 Synthesis of 1- (4-cyano-phenyl) -3- (4-dipropylaminobutyl) -perylene 581.4 mg of the compound obtained in Example 1-2 was dissolved in 17 ml of anhydrous toluene. Then, 485.7 mg of 4-bilidenaminobenzo-tolyl (manufactured by Aldrich) was added. The mixture was stirred at room temperature for 1.5 hours. After the reaction, the solvent was distilled off. The residue was chromatographed on silica gel (chloroform / ethyl acetate).
- Example 12-1 466.4 mg of the compound obtained in Example 12-1 was dissolved in anhydrous THF (14 ml) and cooled with ice. Thereto, 223. lmg of lithium aluminum hydride was added. Stirred at room temperature for 2.5 hours. The reaction was stopped with ethyl acetate. An aqueous solution of sodium potassium tartrate was added and stirred. Extracted with black-mouthed form. Washed with saturated saline. Dried over magnesium sulfate. The solvent was distilled off. The residue was purified by silica gel chromatography (form: form / methanol) to obtain 195 mg of the title compound as a yellow oil.
- Example 12-3 10 mg of the compound obtained in Example 12-3 was dissolved in 4.0 ml of anhydrous methanol. 41.8 mg of 1-methyl-2-imidazolecarboxaldehyde and 47.1 mg of sodium cyanoborohydride were added. The pH was adjusted to 5 with acetic acid. Stirred at room temperature for 20 hours. After the reaction, the solvent was distilled off. The lmol / 1 sodium hydroxide aqueous solution was extracted with syrup and porcine form. Dried over magnesium sulfate. The solvent was distilled off. The residue was purified by silica gel chromatography (chloroform / ethyl acetate). Treatment with hydrochloric acid gave 80.3 mg of the hydrochloride of the title compound as a white solid.
- Example 13-1 366 mg of the compound obtained in Example 13-1 was dissolved in 7.0 ml of DMF, and 44.3 mg of 60% sodium hydride was added thereto, followed by stirring for 1 hour. Thereafter, methyl iodide 2221 was added little by little, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with saturated sodium bicarbonate, extracted with chloroform, washed with saturated saline, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure.
- Example 13-5 232 mg of the compound obtained in Example 13-5 was dissolved in 3.0 ml of a 40% methylamine / methanol solution, and the mixture was stirred at room temperature for 20 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, and washed with lmol / 1 aqueous sodium hydroxide solution. The mixture was extracted with black hole form, and the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (form: methanol / water) to obtain 17.0 mg of the title compound as a pale yellow oil.
- Example 13-6 17.0 mg of the compound obtained in Example 13-6 was dissolved in 0.5 ml of methanol, and trimethyl orthoformate 201 and 6.4 mg of 2-imidazolecarboxaldehyde were added, followed by stirring at room temperature for 1 hour. After cooling to 0 ° C., 6.0 mg of sodium borohydride was added, the temperature was returned to room temperature, and the mixture was stirred for 30 minutes. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with a saturated aqueous solution of sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure.
- Example 14-4 224 mg of the compound obtained in Example 14-4 was dissolved in 2.2 ml of methanol, and 2.2 ml of a 4 mol / l hydrogen chloride / dioxane solution was added. The mixture was stirred at room temperature for 1 hour. After the reaction, the solvent was distilled off under reduced pressure. Treated with anion exchange resin (Amber Rai HRA-410).
- Example 10-2 83.50 g of the compound obtained in Example 10-2 was suspended in 250 ml of DMF, and at -30 ° C, 49.00 g of sodium t-butoxide was added. Further, 95.0 g of phthalimide potassium salt was obtained. Thereafter, the mixture was stirred at 70 ° C. for 2 hours. After the reaction, the mixture was poured into 800 ml of water, and the precipitated crystals were filtered, washed with water and dried to obtain 101.5 g of the title compound as a white solid.
- Example 14-5 36.0 mg of the compound obtained in Example 14-5 was dissolved in 0.6 ml of chloroform, and 180 mg of manganese dioxide (manufactured by Iridaku) was added, followed by stirring at room temperature for 3 hours. After the reaction, the mixture was filtered through celite to distill off the solvent.
- manganese dioxide manufactured by Iridaku
- Example 15 4- ⁇ [(3,5-dimethyl-pyridine-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -N- (4-dipropylamino Synthesis of methyl-phenyl) -benzamide [Compound No.15]
- Example 15-1 Synthesis of (4-tro-benzyl) -dipropyl-amine
- 4-Nitrobenzylamine hydrochloride was desalted to obtain 3.94 g of a free form. This was dissolved in 80 ml of anhydrous methanol, and 5.88 g of sodium cyanoborohydride, 7.18 ml of trimethyl orthoformate and 4.67 ml of propionaldehyde were added and stirred at room temperature under a nitrogen atmosphere for 2 hours. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, a saturated aqueous solution of sodium hydrogen carbonate was added, and the mixture was stirred for a while.
- Example 15-3 545 mg of the compound obtained in Example 15-3 was dissolved in 10 ml of anhydrous methanol, 10.0 ml of a 4 mol / l hydrogen chloride / dioxane solution was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off. To this, an lmol / 1 sodium hydroxide aqueous solution was extracted with syrup, washed with saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, thereby obtaining the subject compound (389 mg) as colorless crystals.
- Example 15-7 4- ⁇ [(3,5 -Dimethyl-pyridine-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) amino] methyl ⁇ -N- (4-dipropylaminomethyl-phenyl) -benzamide [Compound No .15]
- Example 15-5 155 mg of the compound obtained in Example 15-5 was dissolved in 3.0 ml of anhydrous methanol, and 33.7 mg of sodium cyanoborohydride, 0.50 ml of acetic acid, and 58.0 mg of the compound obtained in Example 15-6 were added. Stirred at room temperature for 2 days. After the completion of the reaction, the solvent was distilled off, dissolved in chloroform, and an aqueous solution of lmol / 1 sodium hydroxide was added and stirred for a while. This was extracted with a black hole form, washed with a saturated aqueous solution of sodium hydrogencarbonate and saturated saline, and the organic layer was dried over anhydrous sodium sulfate.
- the solvent was distilled off, and the residue was purified by silica gel column chromatography (chloroform / ethyl acetate) and treated with hydrochloric acid to obtain the hydrochloride (174 mg) of the subject compound as a white solid.
- reaction solution was cooled to 0 ° C.
- 4.43 g of m-chloroperbenzoic acid was added and stirred at room temperature for 2.5 hours.
- To the reaction solution was added lmol / 1 sodium hydroxide sodium hydroxide aqueous solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. The drying agent was filtered off, and the solvent was distilled off.
- Example 16-2 4- ⁇ [(5-ethyl-pyridine-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -N- (4- Synthesis of dipropylaminomethyl-phenyl) -benzamide
- the solvent was distilled off, and the residue was purified by silica gel column chromatography (chloroform / ethyl acetate) and treated with hydrochloric acid to obtain the hydrochloride (222 mg) of the subject compound as a white solid.
- Example 17-1 2.253 g of the compound obtained in Example 17-1 was dissolved in 11 ml of anhydrous THF, and 55.4 ml of lmol / 1 hexane THF complex / THF solution (manufactured by Kanto Iridaku Co., Ltd.) was added thereto. Heated to reflux 1 ⁇ . After cooling, methanol was removed and the solvent was distilled off. The mixture was heated at reflux for 3 hours. After the reaction, the mixture was cooled on ice, and a lmol / 1 aqueous sodium hydroxide solution and 27% aqueous ammonia were added. Black mouth form Extracted. After drying over magnesium sulfate, the solvent was distilled off.
- the medium was distilled off.
- the residue was purified by silica gel chromatography (form: ethyl acetate / ethyl acetate) to give the title compound (220 mg) as a colorless oil.
- Example 17-6 220 mg of the compound obtained in Example 17-6 was dissolved in 8.8 ml of anhydrous THF, and 106 mg of lithium aluminum hydride was added. Stirred at room temperature for 2 hours. After the reaction, ethyl acetate was added. An aqueous solution of sodium potassium tartrate was added and stirred. A black-mouthed form was extracted. It was dried over magnesium sulfate and the solvent was distilled off.
- Example 17-7 104 mg of the compound obtained in Example 17-7 was dissolved in 4.0 ml of anhydrous methanol, and 42.9 mg of 1-methyl-2-imidazolecarboxaldehyde and 49.0 mg of sodium cyanoborohydride were heated. The pH was adjusted to 5 with acetic acid. Stirred at room temperature for 16.5 hours. After the reaction, the solvent was distilled off. A lmol / 1 sodium hydroxide aqueous solution was added, and the mixture was extracted with black-mouth form. Dried over magnesium sulfate. The solvent was distilled off. The residue was purified by silica gel chromatography (chloroform / ethyl acetate) and treated with hydrochloric acid to obtain the hydrochloride (115 mg) of the subject compound as a white solid.
- the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium hydrogen carbonate, and a saturated saline solution, and then dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (form / methanol in the mouth) to obtain 381 mg of the title compound as a brown oil.
- Example 18-3 380 mg of the compound obtained in Example 18-3 was dissolved in 7.6 ml of DMF, and 60.0 mg of 60% sodium hydride was added thereto, followed by stirring for 1 hour. Thereafter, 213 mg of methyl iodide was added little by little, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with a saturated aqueous solution of sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (form: methanol / water) to obtain 83.0 mg of the title compound as a brown solid.
- Example 18-4 83.0 mg of the compound obtained in Example 18-4 was dissolved in 1.0 ml of methanol, and 1.0 ml of a 4 mol / l hydrogen chloride / dioxane solution was added, followed by stirring at room temperature for 6 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in methanol, and the free form was obtained with an anion exchange resin (Amberlite IRA-410). The fat is filtered off, the filtrate is evaporated under reduced pressure, and the residue is purified by silica gel column chromatography (form / ethyl acetate) to give the title compound. 44.0 mg of the compound was obtained as a brown solid.
- Example 19-1 6-cyano-imidazo [1,2-a] pyridine -Synthesis of 2-carboxylic acid ethyl ester
- 2-amino-5-cyanopyridine was dissolved in 30 ml of ethanol, and 3.90 g of 3-bromo-2-oxo-propionic acid ethyl ester was added, followed by heating under reflux for 7 hours.
- the concentrated residue was dissolved in a minimum amount of a 10% hydrogen chloride / methanol solution, and the pH was adjusted to 8 with a saturated aqueous sodium hydrogen carbonate solution.
- the precipitate was collected by filtration to give the title compound (3.81 g) as a pale-yellow solid.
- Example 19-2 6-cyano-imidazo [1 Synthesis of [, 2-a] pyridine-2-carboxylic acid (4-dipropylamino-butyl) -amide
- Example 263 mg of the compound obtained in Example 1-2 was dissolved in 4.0 ml of dichloromethane, and 1.08 ml of a 15% trimethylaluminum / hexane solution was added dropwise thereto, followed by stirring at room temperature for 15 minutes. To this solution was added 300 mg of the compound obtained in Example 19-1, and the mixture was further stirred for 20 hours. The mixture was heated to 40 ° C and stirred for further 7 hours, after which the mol / l hydrochloric acid was stopped from the reaction and extracted with chloroform. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate, water and saturated saline, and dried over anhydrous sodium sulfate. The residue obtained by evaporating the solvent was purified by silica gel column chromatography (form: form / methanol) to obtain 237 mg of the title compound as a yellow solid.
- Example 19-5 6 - ⁇ [(1 ⁇ -imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -5,6,7,8-tetrahydro-imidazo [1,2- a] Synthesis of pyridine-2-carboxylic acid (4-dipropylamino-butyl) -amide [dye conjugate No.19]
- Example 19-4 19.6 mg of the compound obtained in Example 19-4 was dissolved in 2.0 ml of methanol, and 6.2 mg of 1-methyl-2-imidazolecarboxaldehyde and 5.9 mg of sodium cyanoborohydride were added. And stirred at room temperature for 3 hours. The reaction was stopped by adding a saturated aqueous solution of sodium hydrogencarbonate, and the mixture was extracted with chloroform. The organic layer was washed with water and saturated saline, and dried with anhydrous sodium sulfate.
- the residue obtained by evaporating the solvent was purified by silica gel column chromatography (chloroform / ethyl acetate), and further treated with hydrochloric acid to obtain 22.0 mg of the hydrochloride of the title compound as a white solid.
- Example 20-1 Synthesis of t-butyl-4- (4- ⁇ dipropylamino ⁇ butylcarbamoyl) benzyl carbamate After dissolving 558 mg of 4- (t-butoxycarbo-amino-methyl) -benzoic acid in 9.0 ml of chloroform, 728 mg of WSCI hydrochloride and 503 mg of HOBt were added under ice cooling and stirred for 15 minutes. A solution of 652 mg of the compound obtained in -2 in 3.0 ml of a formaldehyde solution was slowly added, and the mixture was stirred at room temperature for 12 hours.
- Example 20-2 Synthesis of 4- (aminomethyl) -N- (4- ⁇ dipropylamino ⁇ butyl) benzamide 715 mg of the compound obtained in Example 20-1 was dissolved in 7.0 ml of methanol. At room temperature, 7.0 ml of a 4 mol / l hydrogen chloride / dioxane solution was added, and the mixture was stirred for 2 hours. After completion of the reaction, the solvent was distilled off, the residue was dissolved in chloroform, and washed with lmol / 1 aqueous sodium hydroxide solution. The organic layer was washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off, thereby obtaining the subject compound (559 mg) as a yellow oily substance.
- Example 20-3 Synthesis of N- (4-dipropylamino-butyl) -4- ⁇ [(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -benzamide
- Example 20-2 538 mg of the compound obtained in Example 20-2 was dissolved in 10 ml of anhydrous methanol, and 600 ⁇ l of trimethyl orthoformate was added at room temperature under a nitrogen atmosphere, and 2.0 ml of a methanol solution of 240 mg of 1-methyl-2-imidazole carboxyaldehyde I got it. After stirring at room temperature for 36 hours, 140 mg of sodium borohydride was added under ice cooling, and the mixture was returned to room temperature and stirred for 1 hour. After completion of the reaction, water was added while stirring under ice cooling. The solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, water was added, and the aqueous layer was extracted with chloroform.
- Example 20-5 N- (4-dipropylamino-butyl) -4- ⁇ [(1-methyl-1H-imidazole-2-ylmethyl)-(5-methyl-pyridine-2-ylmethyl) -amino]- Synthesis of Methyl ⁇ -benzamide
- Example 20-3 782 mg of the compound obtained in Example 20-3 was dissolved in 12 ml of anhydrous methanol, and 380 mg of sodium cyanoborohydride and 1.5 ml of acetic acid were added. At -10 ° C, 2.0 ml of a methanol solution of 289 mg of the compound obtained in Example 20-4 was added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. After completion of the reaction, the reaction was stopped by adding water. The solvent was distilled off under reduced pressure, and the residue was diluted with chloroform and lmol / 1 sodium hydroxide aqueous solution to adjust the pH of the aqueous layer to about 10, and the aqueous layer was extracted with chloroform.
- Example 21 N- (4-dipropylamino-butyl) -N- (4- ⁇ [(1H-imidazole-2-ylmethyl Synthesis of)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -benzyl) -methanesulfonamide [I-Danied Compound No.21]
- Example 21-1 4- ⁇ [t- Synthesis of Butoxycarbol- (1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ benzoic acid methyl ester
- the resultant was dissolved in 150 ml, and 1.45 g of 60% sodium hydride and 2.70 ml of methyl iodide were collected and stirred at room temperature for 18 hours.
- the reaction solution was added to a saturated aqueous solution of sodium chloride, extracted with chloroform, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (chloroform / methanol) to obtain 2.31 g of the title compound as a brown solid.
- Lithium aluminum hydride l.Og was suspended in 95.1 ml of THF, and 3.17 g of the compound obtained in Example 21-1 was suspended in THF.
- Example 22 N- (4-dipropylamino-butyl) -N- (4- ⁇ [(1H-imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ Synthesis of -benzyl) -4-methyl-benzenesulfonamide [Compound No. 22]
- Example 22-1 (4- ⁇ [(4-dipropylamino-butyl)-(toluene-4-sulfol) -amino] ] -Methyl ⁇ -benzyl)-(1-Methyl-1H-imidazole-2-ylmethyl) -t-butylester
- Example 21-4 182.0 mg of the compound obtained in Example 21-4 was dissolved in 5.3 ml of dichloromethane, 0.104 ml of triethylamine and 107.2 mg of p-toluenesulfuryl chloride were added, and the mixture was stirred at room temperature for 0.5 hour.
- Example 23 N-ethyl-N- (4- ⁇ [(1H-imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -benzyl) -N ,,, -Dipropyl-butane-1,4-diamine [Synthesis Compound ⁇ .23]
- Example 23-1 4- (t-Butoxycarbonylamino-methyl) -benzoic acid methyl ester The synthesized 4-aminomethylbenzoic acid methyl ester hydrochloride was desalted to obtain 20.2 g of a free compound.
- Example 23-2 Synthesis of (4-hydroxymethyl-benzyl) -hydroxylbamate t-butyl ester Obtained in Example 23-1 35.7 g of the obtained compound was dissolved in 800 ml of anhydrous THF, and 10.2 g of lithium aluminum hydride was added in an ice bath, followed by stirring under a nitrogen atmosphere for 2 days. After completion of the reaction, methanol and then an aqueous solution of sodium potassium tartrate were stirred overnight. This was extracted with a filter, washed with saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, thereby obtaining the subject compound (29.2 g) as colorless crystals.
- Example 23-2 17.6 g of the compound obtained in Example 23-2 was dissolved in 400 ml of chloroform and 88.2 g of manganese dioxide (chemically treated product) was added, followed by stirring at room temperature overnight. After completion of the reaction, the mixture was filtered through celite, and the solvent was distilled off to obtain 20.4 g of the title compound as colorless crystals.
- Example 23-4 Synthesis of t-butyl ⁇ 4-[(4-dipropylamino-butylamino) -methyl] -benzyl ⁇ -hydroxylbamate
- Example 23-5 Synthesis of (4- ⁇ [(4-dipropylamino-butyl) -ethyl-amino] -methyl ⁇ -benzyl) -t-butyl ester of carbamic acid
- Example 23-6 219 mg of the compound obtained in Example 23-6 was dissolved in 5.0 ml of anhydrous methanol, and 112 ⁇ l of trimethyl orthoformate and 72.4 mg of 2-imidazolecarboxaldehyde were stirred overnight at room temperature under a nitrogen atmosphere of kamoto. Then, 12.3 mg of sodium borohydride was added in an ice bath, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, distilled water was added and the mixture was stirred for a while. This was extracted with chloroform, washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, and the organic layer was dried over anhydrous sodium sulfate. The solvent was distilled off, thereby obtaining the subject compound (317 mg) as a yellow oily substance.
- Example 23-8 N-ethyl-N- (4- ⁇ [(1H-imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ Benzyl) -N ', ⁇ ' -Dipropyl-butane-1, 4-diamine
- Example 24-2 88.8 mg of the compound obtained in Example 24-2 was dissolved in 3.5 ml of anhydrous THF. Thereto, 36.4 mg of lithium aluminum hydride was added and stirred at room temperature for 4 hours. The mixture was further stirred at 60 ° C for 2 hours. After the reaction, ethyl acetate was added. An aqueous solution of sodium potassium tartrate was added and stirred. A black-mouthed form was extracted. Dried over magnesium sulfate. The solvent was distilled off under reduced pressure.
- Example 24-3 45.5 mg of the compound obtained in Example 24-3 was dissolved in 1.8 ml of anhydrous methanol. 16.5 mg of 1-methyl-2-imidazolecarboxaldehyde and 18.9 mg of sodium cyanoborohydride were added thereto. The pH was adjusted to 5 with acetic acid. Stirred at room temperature for 24 hours. After the reaction, the solvent was distilled off, and a lmol / 1 sodium hydroxide aqueous solution was extracted and extracted with chloroform. Magnesium sulfate The solvent was distilled off after drying with steam.
- Example 26 1- (4-Dipropylamino-butyl) -3- (4- ⁇ [(1 ⁇ -imidazole-2-ylmethyl)-(1-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇
- Example 26-1 Synthesis of 3- (4-cyano-phenyl) -1- (4-dipropylamino-butyl) Synthesis of 1-methyl-urea
- Example 27-1 37.8 mg of the compound obtained in Example 27-1 was dissolved in 1.5 ml of ethanol. 0.4 ml of a 1 mol / l sodium hydroxide aqueous solution of sodium hydroxide was prepared. 3.8 mg of Raney nickel was added and stirred at room temperature for 4 hours under a hydrogen atmosphere. After the reaction, the mixture was filtered through celite, and the solvent was distilled off. A black-mouthed form was extracted. The solvent was distilled off.
- 3 ⁇ 4 3 ⁇ 4 3 ⁇ 4S Hd ⁇ . ⁇ Hf Sui 8'9I Ma fH mine mine, ⁇ S'fl t6
- Example 29-2 883 mg of the compound obtained in Example 29-2 was dissolved in 18 ml of methanol, 9.0 ml of 1 mol / 1 sodium hydroxide aqueous solution was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in lmol / 1 hydrochloric acid, extracted with chloroform, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was dried in vacuo to obtain 820 mg of the title compound as a white solid.
- 1-Dipropylaminomethyl-benzamide Compound l.Olg obtained in Example 29-3, 973 mg of WSCI hydrochloride, and 894 mg of HOBt were dissolved in 30 ml of chloroform and stirred for 2 hours.
- Example 29-1 To this was added 445 mg of the compound obtained in Example 29-1, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with a saturated aqueous solution of ammonium chloride, a saturated aqueous solution of sodium hydrogen carbonate, and a saturated saline solution, and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (form: ethyl acetate / ethyl acetate) to obtain 613 mg of the title compound as an orange solid.
- Example 29-4 613 mg of the compound obtained in Example 29-4 was dissolved in 18 ml of THF, and 105 mg of 60% sodium hydride was added thereto. Thereafter, 373 mg of methyl iodide was added little by little, and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, the residue was dissolved in chloroform, washed with water and extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (160 mg) as a brown solid.
- Example 29-6 93.5 mg of the compound obtained in Example 29-6 was dissolved in 4.0 ml of methanol, and 100 ⁇ l of trimethyl orthoformate and 31.7 mg of 2-imidazolecarboxaldehyde were added and stirred at room temperature for 1 hour. After cooling to 0 ° C., 13.2 mg of sodium borohydride was added. After returning to room temperature, the mixture was stirred for 30 minutes.
- Example 30-2 Synthesis of 6-formyl-imidazo [1,2-a] pyridine-2-carboxylic acid ethyl ester, 9.66 (lH, s).
- Example 30-1 To a solution of 318 mg of the compound obtained in Example 30-1 in 8.0 ml of ethanol was added 0.33 ml of ethyl 3-bromo-2-oxo-propionate, and the mixture was stirred at room temperature for 18 hours. The solvent was distilled off. The residue was purified by silica gel column chromatography (form: form / methanol) to obtain 230 mg of the title compound as a yellow solid.
- Example 30-3 6- ⁇ [(l-methyl-1H-imidazole-2-ylmethyl) -amino] -methyl ⁇ -imidazo Synthesis of [1,2-a] pyridine-2-carboxylic acid (4-dipropylamino-butyl) -amide
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/591,722 US7932281B2 (en) | 2004-03-10 | 2005-03-10 | Amine-based compound and use thereof |
CA2558600A CA2558600C (en) | 2004-03-10 | 2005-03-10 | A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4 |
KR1020067020943A KR101149124B1 (ko) | 2004-03-10 | 2005-03-10 | 아민계 염기성 화합물과 그의 용도 |
CN2005800149250A CN1950343B (zh) | 2004-03-10 | 2005-03-10 | 胺系碱性化合物及其用途 |
JP2006510807A JP3977411B2 (ja) | 2004-03-10 | 2005-03-10 | アミン系塩基性化合物とその用途 |
EP05720460.4A EP1724263B1 (en) | 2004-03-10 | 2005-03-10 | Basic amine compound and use thereof |
US13/051,248 US20110172212A1 (en) | 2004-03-10 | 2011-03-18 | Amine-based compound and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004068229 | 2004-03-10 | ||
JP2004-068229 | 2004-03-10 | ||
JP2004-350599 | 2004-12-03 | ||
JP2004350599 | 2004-12-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/051,248 Continuation US20110172212A1 (en) | 2004-03-10 | 2011-03-18 | Amine-based compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005085209A1 true WO2005085209A1 (ja) | 2005-09-15 |
Family
ID=34921763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004189 WO2005085209A1 (ja) | 2004-03-10 | 2005-03-10 | アミン系塩基性化合物とその用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US7932281B2 (ja) |
EP (1) | EP1724263B1 (ja) |
JP (1) | JP3977411B2 (ja) |
KR (1) | KR101149124B1 (ja) |
CN (1) | CN1950343B (ja) |
CA (1) | CA2558600C (ja) |
WO (1) | WO2005085209A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176227B2 (en) | 2002-09-11 | 2007-02-13 | Kureha Corporation | Amine compounds and use thereof |
WO2007023788A1 (ja) * | 2005-08-22 | 2007-03-01 | Kureha Corporation | アミン誘導体、その製造方法及び用途 |
WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
JP2008514708A (ja) * | 2004-09-29 | 2008-05-08 | アノーメド インコーポレイテッド | ケモカイン結合複素環式化合物の塩及びその使用方法 |
US7781481B2 (en) | 2005-12-22 | 2010-08-24 | Novartis Ag | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors |
EP2100890A4 (en) * | 2006-10-26 | 2010-09-08 | Inst Quimic De Sarria Cets | NEW POLYNITROGENATED SYSTEMS AS ANTI-HIV MEDIUM |
WO2010119741A1 (ja) * | 2009-04-17 | 2010-10-21 | 株式会社クレハ | 外用剤 |
US7951816B2 (en) | 2004-08-27 | 2011-05-31 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
WO2012046653A1 (ja) | 2010-10-06 | 2012-04-12 | 株式会社クレハ | アミン系化合物とその用途 |
AU2009322164B2 (en) * | 2008-12-05 | 2014-12-18 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US7498323B2 (en) * | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
CA2593993C (en) | 2004-12-30 | 2014-07-29 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
EP1836199A1 (en) * | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases |
WO2007077435A1 (en) | 2005-12-30 | 2007-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
JP2009542608A (ja) * | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
CA2913840C (en) * | 2007-04-11 | 2019-03-05 | Canbas Co., Ltd. | Compounds with anti-cancer activity |
KR101632318B1 (ko) * | 2009-11-05 | 2016-06-27 | 재단법인 의약바이오컨버젼스연구단 | 벤조헤테로사이클 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 및 치료용 조성물 |
WO2013033310A1 (en) * | 2011-08-31 | 2013-03-07 | Theodore Mark Kamenecka | Modulators of rev-erb |
KR20130032847A (ko) * | 2011-09-23 | 2013-04-02 | 주식회사유한양행 | 이미드를 포함하는 벤조싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물 |
MX2015014688A (es) * | 2013-04-22 | 2016-02-19 | Abbvie Inc | Tiazoles y usos de los mismos. |
EP3038617A1 (en) | 2013-08-30 | 2016-07-06 | Ramot at Tel-Aviv University Ltd. | Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling |
GB201613946D0 (en) | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
US11046731B2 (en) * | 2018-01-18 | 2021-06-29 | Hong Kong Baptist University | Zinc-binder based EBNA1-specific compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056729A1 (en) * | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
WO2002022600A2 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
WO2002094261A1 (en) * | 2001-05-24 | 2002-11-28 | Kureha Chemical Industry Company, Limited | Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
WO2003029218A1 (fr) * | 2001-09-28 | 2003-04-10 | Kureha Chemical Industry Company, Limited | Compose azote et utilisation correspondante |
WO2004024697A1 (ja) * | 2002-09-11 | 2004-03-25 | Kureha Chemical Industry Company, Limited | アミン化合物及びその用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US783391A (en) * | 1904-05-23 | 1905-02-21 | Eriez Stove And Mfg Company | Gas-burner for cooking-stoves. |
US3634316A (en) * | 1968-08-23 | 1972-01-11 | Showa Denko Kk | Sulfur-vulcanizable natural and synthetic rubbery polymers containing xylylene diamines as antiozonants |
DE3577700D1 (de) | 1984-11-30 | 1990-06-21 | Shosuke Okamoto | Lysinderivat und proteinase-inhibitor. |
US5086096A (en) * | 1990-02-22 | 1992-02-04 | E. I. Du Pont De Nemours And Company | Polyacetal compositions stabilized with microcrystalline or fibrous cellulose |
US5086069A (en) | 1990-02-05 | 1992-02-04 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptide and pseudopeptide derivatives |
JP3719612B2 (ja) | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
DE4331135A1 (de) * | 1993-09-14 | 1995-03-16 | Bayer Ag | Neue antiviral wirksame valinhaltige Pseudopeptide |
JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
US6077954A (en) * | 1996-08-01 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Substituted heterocyclic compounds |
AR008290A1 (es) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
AU1684099A (en) | 1997-12-26 | 1999-07-19 | Kureha Chemical Industry Co., Ltd. | Amino acid derivatives |
TR200100141T2 (tr) * | 1998-04-16 | 2001-06-21 | Texas Biotechnology Corporation | İntegrinlerin reseptörlerine bağlanmasını engelleyen bileşikler |
WO2000006086A2 (en) | 1998-07-31 | 2000-02-10 | The Trustees Of Columbia University In The City Of New York | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
MXPA02001160A (es) | 1999-08-04 | 2002-07-02 | Millennium Pharm Inc | Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos. |
CN1423635A (zh) * | 2000-04-14 | 2003-06-11 | 吴羽化学工业株式会社 | 含氮化合物以及使用该化合物的抗病毒药 |
US6734191B2 (en) * | 2000-09-15 | 2004-05-11 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
AU7622500A (en) | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
EP1363890A4 (en) | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION |
US8000532B2 (en) * | 2007-02-28 | 2011-08-16 | Medtronic, Inc. | Digital pen to capture data in ambulatory monitored patients |
-
2005
- 2005-03-10 JP JP2006510807A patent/JP3977411B2/ja not_active Expired - Fee Related
- 2005-03-10 EP EP05720460.4A patent/EP1724263B1/en not_active Expired - Lifetime
- 2005-03-10 KR KR1020067020943A patent/KR101149124B1/ko not_active Expired - Lifetime
- 2005-03-10 WO PCT/JP2005/004189 patent/WO2005085209A1/ja active Application Filing
- 2005-03-10 CA CA2558600A patent/CA2558600C/en not_active Expired - Fee Related
- 2005-03-10 US US10/591,722 patent/US7932281B2/en not_active Expired - Fee Related
- 2005-03-10 CN CN2005800149250A patent/CN1950343B/zh not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,248 patent/US20110172212A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000056729A1 (en) * | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
WO2002022600A2 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
WO2002094261A1 (en) * | 2001-05-24 | 2002-11-28 | Kureha Chemical Industry Company, Limited | Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
WO2003029218A1 (fr) * | 2001-09-28 | 2003-04-10 | Kureha Chemical Industry Company, Limited | Compose azote et utilisation correspondante |
WO2004024697A1 (ja) * | 2002-09-11 | 2004-03-25 | Kureha Chemical Industry Company, Limited | アミン化合物及びその用途 |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176227B2 (en) | 2002-09-11 | 2007-02-13 | Kureha Corporation | Amine compounds and use thereof |
US7833991B2 (en) | 2002-09-11 | 2010-11-16 | Kureha Corporation | Amine compound and use thereof |
US7951816B2 (en) | 2004-08-27 | 2011-05-31 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US8822459B2 (en) | 2004-08-27 | 2014-09-02 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
JP2012131820A (ja) * | 2004-08-27 | 2012-07-12 | Ono Pharmaceut Co Ltd | 塩基性基を含有する化合物およびその用途 |
JP2008514708A (ja) * | 2004-09-29 | 2008-05-08 | アノーメド インコーポレイテッド | ケモカイン結合複素環式化合物の塩及びその使用方法 |
US7977512B2 (en) | 2005-08-22 | 2011-07-12 | Kureha Corporation | Amine derivative, and production method and use thereof |
WO2007023788A1 (ja) * | 2005-08-22 | 2007-03-01 | Kureha Corporation | アミン誘導体、その製造方法及び用途 |
WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
EP1942108A4 (en) * | 2005-10-28 | 2010-10-20 | Ono Pharmaceutical Co | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF |
US8614323B2 (en) | 2005-10-28 | 2013-12-24 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
US8871210B2 (en) | 2005-10-28 | 2014-10-28 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
US8519124B2 (en) | 2005-11-18 | 2013-08-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
EP1961744A4 (en) * | 2005-11-18 | 2009-07-01 | Ono Pharmaceutical Co | CONNECTION WITH BASIC GROUPS AND ITS USE |
US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
JP5217438B2 (ja) * | 2005-11-18 | 2013-06-19 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
US7781481B2 (en) | 2005-12-22 | 2010-08-24 | Novartis Ag | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors |
JP5257068B2 (ja) * | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
EP2100890A4 (en) * | 2006-10-26 | 2010-09-08 | Inst Quimic De Sarria Cets | NEW POLYNITROGENATED SYSTEMS AS ANTI-HIV MEDIUM |
AU2009322164B2 (en) * | 2008-12-05 | 2014-12-18 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
WO2010119741A1 (ja) * | 2009-04-17 | 2010-10-21 | 株式会社クレハ | 外用剤 |
WO2012046653A1 (ja) | 2010-10-06 | 2012-04-12 | 株式会社クレハ | アミン系化合物とその用途 |
JPWO2012046653A1 (ja) * | 2010-10-06 | 2014-02-24 | 株式会社クレハ | アミン系化合物とその用途 |
US8722719B2 (en) | 2010-10-06 | 2014-05-13 | Kureha Corporation | Amine compound and use for same |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
US12194432B2 (en) | 2018-02-05 | 2025-01-14 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Also Published As
Publication number | Publication date |
---|---|
EP1724263B1 (en) | 2014-03-05 |
CN1950343A (zh) | 2007-04-18 |
JPWO2005085209A1 (ja) | 2007-12-13 |
CA2558600C (en) | 2013-07-09 |
US20110172212A1 (en) | 2011-07-14 |
US20070208007A1 (en) | 2007-09-06 |
US7932281B2 (en) | 2011-04-26 |
KR101149124B1 (ko) | 2012-05-25 |
CA2558600A1 (en) | 2005-09-15 |
KR20060131969A (ko) | 2006-12-20 |
CN1950343B (zh) | 2013-06-19 |
EP1724263A4 (en) | 2009-05-06 |
EP1724263A1 (en) | 2006-11-22 |
JP3977411B2 (ja) | 2007-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005085209A1 (ja) | アミン系塩基性化合物とその用途 | |
JP3714948B2 (ja) | アミン化合物及びその用途 | |
BR112020001713A2 (pt) | inibidores seletivos de inflamassoma de nlrp3 | |
CN101605783A (zh) | 作为药物、药物组合物尤其作为ikk抑制剂的新型n,n’-2,4-二苯胺基嘧啶衍生物及其制备 | |
WO1988007045A1 (en) | Derivatives of physiologically active substance k-252 | |
AU2003272879A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
WO2005058790A1 (ja) | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 | |
JP6559699B2 (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
AU2002238855B2 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
WO2021203023A1 (en) | Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) | |
CN110234640B (zh) | 作为抗癌剂的苯并咪唑衍生物 | |
EP4212524A1 (en) | Cd73 inhibitor and application thereof in medicine | |
AU2011345969B2 (en) | Novel substituted isoquinoline derivative | |
AU2017213993B2 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
WO2006008874A1 (ja) | アミノチアゾール骨格を有するCdk4,6選択的阻害剤 | |
JP5778133B2 (ja) | シクロプロパンカルボン酸誘導体 | |
CA3045491A1 (en) | Integrin antagonists | |
EP2013186A1 (en) | Imidazole derivatives for use as edg-1 antagonists | |
JP7343622B2 (ja) | Fgfrとvegfr二重阻害剤としての縮合環系化合物 | |
CN107266405A (zh) | 用于制备c‑fms激酶抑制剂的方法 | |
CN115260194B (zh) | 新型egfr降解剂 | |
JP4953298B2 (ja) | アミン系塩基性化合物とその用途 | |
JP4028885B2 (ja) | アミン系塩基性化合物とその用途 | |
JP2006151812A (ja) | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 | |
CN115515958A (zh) | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510807 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2558600 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005720460 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067020943 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10591722 Country of ref document: US Ref document number: 2007208007 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580014925.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005720460 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067020943 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10591722 Country of ref document: US |